C71T
CANCELLED SECTION 71
10/07/2026
Voltar para busca
Dado oficial do USPTO
BUVIDAL
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
45
Atualização mais recente
04/08/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
28/05/2018
Data de registro
24/12/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/07/2026
Última transação
04/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
09
Localização do titular
SE
Examinador
STEDMAN, CORI
Unidade examinadora
N50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Camurus AB
Representantes
Karen Kreider Gaunt Dinsmore & Shohl LLP
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationsfor the treatment of substance use disorderssubstance dependencesubstance withdrawalsubstance addictionsubstance overdosefor the treatment of opiate and chemical addictionsfor the treatment of co-morbidities associated with substance use disordersfor the treatment of mental health diseases and disordersfor the treatment of central nervous system diseases and disordersfor the management and relief of pain; veterinary pharmaceutical preparationsfor the treatment of substance use disorderssubstance dependencesubstance withdrawalsubstance addictionsubstance overdosefor the treatment of opiate and chemical addictionsfor the treatment of co-morbidities associated with substance use disordersfor the treatment of mental health diseases and disordersfor the treatment of central nervous system diseases and disordersfor the management and relief of pain; sanitary preparations for medical purposes; dietetic substancesnamely dietetic beverages and dietetic sugar adapted for medical usefor the treatment of substance use disorderssubstance dependencesubstance withdrawalsubstance addictionsubstance overdosefor the treatment of opiate and chemical addictionsfor the treatment of co-morbidities associated with substance use disordersfor the treatment of mental health diseases and disordersfor the treatment of central nervous system diseases and disordersfor the management and relief of pain; plasters for medical purposesmaterials for dressingsmedical dressingsall for the treatment of substance use disorderssubstance dependencesubstance withdrawalsubstance addictionsubstance overdosefor the treatment of opiate and chemical addictionsfor the treatment of co-morbidities associated with substance use disordersfor the treatment of mental health diseases and disordersfor the treatment of central nervous system diseases and disordersfor the management and relief of pain; disinfectants; preparations for destroying vermin; fungicidesherbicides
Classe 42
Scientific and technological services and researchdevelopment and design relating theretoscientific researchanalysis and testing in the field of pharmaceutical preparations and medicinesall for use in the fields of treatment of substance use disorderssubstance dependencesubstance withdrawalsubstance addictionsubstance overdosetreatment of opiate and chemical addictionstreatment of co-morbidities associated with substance use disorderstreatment of mental health diseases and disorderstreatment of central nervous system diseases and disordersmanagement and relief of pain; chemical laboratories; chemical researchchemical analysis; research in the fields of medicinesfoodscosmetics and biotechnology; development of technical know-howtechnical adviceinformationsupport and consultancy namelyscientific researchanalysis and testing in the field of pharmaceutical preparations and medicineall in the fields of the treatment of substance use disorderssubstance dependencesubstance withdrawalsubstance addictionsubstance overdosethe treatment of opiate and chemical addictionsthe treatment of co-morbidities associated with substance use disordersthe treatment of mental health diseases and disordersthe treatment of central nervous system diseases and disordersmanagement and relief of pain
Classe 44
Medical services; veterinary services; consultancy relating to medicines in the nature of providing medical consultancy services
Publicações
Histórico de despachos e eventos da marca no USPTO.
45 publicações encontradas
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
14/03/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
24/12/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/12/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
04/12/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/12/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/12/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/12/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/12/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
24/07/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
24/04/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/04/2020
FIMP
FINAL DISPOSITION PROCESSED
06/04/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24/03/2020
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/01/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
24/12/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
18/12/2019
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
18/12/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/10/2019
PUBO
PUBLISHED FOR OPPOSITION
08/10/2019
GPNX
NOTIFICATION PROCESSED BY IB
04/10/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
18/09/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
18/09/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/09/2019
ALIE
ASSIGNED TO LIE
05/09/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
29/08/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/08/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/08/2019
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
27/08/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/06/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/06/2019
CNFR
FINAL REFUSAL MAILED
22/04/2019
CNFR
FINAL REFUSAL WRITTEN
21/04/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/03/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/03/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
15/03/2019
RFNP
REFUSAL PROCESSED BY IB
12/10/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
25/09/2018
RFRR
REFUSAL PROCESSED BY MPU
25/09/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
18/09/2018
CNRT
NON-FINAL ACTION WRITTEN
17/09/2018
DOCK
ASSIGNED TO EXAMINER
17/09/2018
MAFR
APPLICATION FILING RECEIPT MAILED
18/07/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/07/2018
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
12/07/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BUVIDAL ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.